Raymond James & Associates
SRNE

Raymond James & Associates’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Raymond James & Associates’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-223,019
Closed -$198K – 4146
2022
Q4 		$198K Sell
223,019
-34,300
-13% -$45.5K ﹤0.01% 3459
2022
Q3 		$404K Buy
257,319
+101,500
+65% +$230K ﹤0.01% 2991
2022
Q2 		$313K Sell
155,819
-11,006
-7% -$19K ﹤0.01% 3203
2022
Q1 		$389K Sell
166,825
-12,932
-7% -$40.3K ﹤0.01% 3234
2021
Q4 		$836K Buy
179,757
+28,000
+18% +$174K ﹤0.01% 2742
2021
Q3 		$1.16M Buy
151,757
+39,300
+35% +$333K ﹤0.01% 2482
2021
Q2 		$1.09M Buy
112,457
+26,186
+30% +$209K ﹤0.01% 2531
2021
Q1 		$713K Sell
86,271
-23,364
-21% -$247K ﹤0.01% 2747
2020
Q4 		$748K Sell
109,635
-8,185
-7% -$65.7K ﹤0.01% 2535
2020
Q3 		$1.31M Sell
117,820
-114,009
-49% -$1.04M ﹤0.01% 2010
2020
Q2 		$1.46M Buy
231,829
+220,579
+1,961% +$844K ﹤0.01% 1919
2020
Q1 		$21K Buy
+11,250
New +$32.4K ﹤0.01% 3397
2016
Q2 		– Sell
-16,000
Closed -$86K – 3106
2016
Q1 		$86K Buy
+16,000
New +$93K ﹤0.01% 2740

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return
Oaktree Capital Management
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $49.5M AUM 28.58% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return
GA
GoalVest Advisory New York $578M AUM 17.41% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return
Valeo Financial Advisors
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 19.15% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $1.09B AUM 22.93% 1-Year Est. Return

Raymond James & Associates's SRNE Position: Q1 2023 in Review

Raymond James & Associates sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 223,019 shares — an estimated $198K sold.

Raymond James & Associates first reported a position in SRNE in Q1 2016 and held it in 13 quarters. The position peaked at $1.46M in Q2 2020. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

  • Raymond James & Associates reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • Raymond James & Associates sold 223,019 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $198K.
  • Raymond James & Associates first reported a position in Sorrento Therapeutics, Inc. in Q1 2016 and held it in 13 quarters.
  • Raymond James & Associates's Sorrento Therapeutics, Inc. position peaked at $1.46M in Q2 2020.
  • 34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Raymond James & Associates's 13F filing for Q1 2023, filed 14 Apr 2023.